-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From June 4th to June 8th this year, the American Society of Clinical Oncology (ASCO) annual meeting will be held online
.
One of the highlight studies recommended by this ASCO is that immunotherapy delays the recurrence of early stage operable non-small cell lung cancer (NSCLC) patients
Lung cancer is one of the cancer types that cause the highest number of deaths in the world, and non-small cell lung cancer (NSCLC) patients account for 85% of the total number of lung cancer patients.
Therefore, the development of therapies for NSCLC has always been a hot spot for cancer therapy development
IMpower010 is a pivotal phase 3 clinical trial for the treatment of patients with early stage NSCLC
.
The trial recruited 1,280 patients with stage IB-IIIA NSCLC who were completely resected.
After cisplatin-based chemotherapy, 1,005 patients were randomized 1:1 to receive atezolizumab (Tecentriq) adjuvant therapy or optimal supportive care
The results showed that compared with the best supportive therapy, atezolizumab as an adjuvant therapy in patients with stage II-IIIA NSCLC with tumor PD-L1 expression >1% reduced the risk of disease recurrence or death by 34% (HR=0.
66, 95) % CI: 0.
According to a Roche press release, this is the first positive phase 3 clinical result obtained by cancer immunotherapy as an adjuvant lung cancer therapy
.
In all patients with stage II-IIIA NSCLC (regardless of PD-L1 expression level), atezolizumab reduced the risk of disease recurrence or death by 21% (HR=0.
79, 95% CI: 0.
64-0.
Based on the data of patients who received at least one dose of atezolizumab or at least one safety assessment in the best supportive treatment group, the researchers found that the incidence of adverse events of any grade in the atezolizumab group and the best supportive treatment group was 92.
7% and 70.
"Although surgery can cure some early-stage lung cancer patients, disease recurrence is still very common
.
Prior to this trial, the only treatment known to reduce the risk of most patients was chemotherapy.
For a small number of patients with EGFR mutations, the choice was Osimitinib treatment
Note: The original text has been deleted
Reference materials:
[1] Pivotal Phase III data at ASCO show Roche's Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning.
Retrieved May 20, 2021, from https://
[2] Immunotherapy Delays Disease Recurrence in Patients With Early-Stage, Resected Non-Small Cell Lung Cancer.
Retrieved May 24, 2021, from https://
